Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia.

ABSTRACT: Heparin-induced thrombocytopenia (HIT) is a life-threatening complication associated with high medical costs. Factor Xa inhibitors gradually replace approved treatment with intravenous direct thrombin inhibitors despite their off-label indication, because of easier management and favorable economic profile. Whether they are cost-effective remains unclear. We evaluated the cost-effectiveness of approved and off-label anticoagulants in patients with suspected HIT, based on census data from the largest Swiss hospital between 2015 and 2018. We constructed a decision tree model that reflects important clinical events associated with HIT. Relevant cost data were obtained from the finance department or estimated based on the Swiss-wide cost tariff. We estimated averted adverse events (AEs) and in

SUBMITTER: Tuleja A 

PROVIDER: S-EPMC9131923 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature